Tanyel Kiziltepe

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

Shiladitya Sengupta, David A. Eavarone, Ishan Capila et al. · Nature · 2005 · 936 citations

Tissue Engineering, Nanomedicine, Nanoparticles +13

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Naoya Mimura, Mariateresa Fulciniti, Güllü Görgün et al. · Blood · 2012 · 431 citations · Full text

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Laurence Catley, Ellen Weisberg, Tanyel Kiziltepe et al. · Blood · 2006 · 340 citations · Full text

Hdac Inhibitors, Proteasome Inhibitor Bortezomib, Cell Death +16

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

Yutaka Okawa, Teru Hideshima, Paul M. Steed et al. · Blood · 2008 · 208 citations · Full text

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i>

Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti et al. · Clinical Cancer Research · 2009 · 204 citations · Full text